Oisín Biotechnologies, a Seattle, WA-based biotechnology company focused on mitigating the effects of age-related diseases, announced the first close of a $15M in Series A funding.
The round was led by AbbVie Ventures. Danjuma Quarless, Ph.D., Associate Director, AbbVie Ventures will join Oisín’s Board of Directors. Darin Messina, Ph.D., Senior Vice President, Aesthetics R&D, AbbVie, will join Oisín’s Scientific Advisory Board.
The company intends to use the funds to advance its pipeline of therapies for age-related diseases toward clinical development.
Led by CEO Matthew Scholz, Oisín is a privately held biotechnology company developing genetic medicines to address age-related diseases. It utilizes the Fusogenix Proteo-Lipid Vehicle (PLV) technology, to deliver DNA directly to cells throughout the body, addressing the damage and detrimental effects caused by the aging process itself. The company’s first therapies focus on eliminating unwanted fat cells and building muscle mass.
FinSMEs
25/07/2024